Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Free Report) – Research analysts at HC Wainwright boosted their FY2028 earnings estimates for shares of Compass Pathways in a report released on Monday, November 9th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $0.10 per share for the year, up from their prior estimate of ($0.23). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for Compass Pathways’ FY2029 earnings at $1.92 EPS and FY2030 earnings at $4.21 EPS.
Several other analysts have also commented on the stock. Royal Bank Of Canada restated an “outperform” rating on shares of Compass Pathways in a report on Wednesday, November 4th. Wall Street Zen raised Compass Pathways from a “sell” rating to a “hold” rating in a research report on Monday. B. Riley Financial upped their target price on Compass Pathways from $17.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. BTIG Research reissued a “buy” rating and issued a $25.00 target price on shares of Compass Pathways in a research report on Tuesday, November 3rd. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Compass Pathways in a research report on Monday, November 9th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Compass Pathways currently has a consensus rating of “Moderate Buy” and an average target price of $23.14.
Compass Pathways Price Performance
Shares of NASDAQ CMPS opened at $8.12 on Tuesday. Compass Pathways has a 1 year low of $4.88 and a 1 year high of $15.87. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.50 and a quick ratio of 1.50. The company’s 50-day moving average is $11.53 and its 200 day moving average is $10.48. The stock has a market capitalization of $1.15 billion, a P/E ratio of -2.33 and a beta of 2.43.
Compass Pathways (NASDAQ:CMPS – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.08.
Hedge Funds Weigh In On Compass Pathways
A number of institutional investors and hedge funds have recently made changes to their positions in CMPS. Orbimed Advisors LLC bought a new stake in Compass Pathways during the 1st quarter valued at about $6,363,000. Affinity Asset Advisors LLC lifted its stake in shares of Compass Pathways by 454.2% in the first quarter. Affinity Asset Advisors LLC now owns 1,108,483 shares of the company’s stock worth $6,130,000 after buying an additional 908,483 shares in the last quarter. Eversept Partners LP bought a new position in shares of Compass Pathways in the first quarter worth approximately $3,749,000. Creek Drive Management Group LLC lifted its stake in shares of Compass Pathways by 91.9% in the third quarter. Creek Drive Management Group LLC now owns 1,328,000 shares of the company’s stock worth $16,520,000 after buying an additional 636,000 shares in the last quarter. Finally, CenterBook Partners LP grew its holdings in shares of Compass Pathways by 454.1% during the third quarter. CenterBook Partners LP now owns 695,943 shares of the company’s stock valued at $8,658,000 after buying an additional 570,349 shares during the last quarter. Institutional investors own 46.19% of the company’s stock.
About Compass Pathways
Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.
See Also
- Five stocks we like better than Compass Pathways
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Compass Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways and related companies with MarketBeat.com's FREE daily email newsletter.
